SEARCH RESULTS FOR:
Sinan Dalli
GENERAL MANAGER, ALSER MADENCILIK
Alser Madencilik speaks to GBR about its foray into chrome mining in Turkey.
Carlos R. Dorticós B.
BUSINESS DIRECTOR, UNIVAR
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
GBR speaks to Univar about the chemical distribution market in Mexico.
Distribution: Streamlining the Channels
Singapore Chemicals 2018
Distributors of Specialty Chemicals in Singapore diversify and adapt to an evolving marketplace.
From Volume to Value: A Shift in Innovation Focus in the U.S.
United States Biopharmaceuticals 2018
Precision medicine and the understanding that every patient is different are driving drug discovery.
Eugene Williams
EXECUTIVE CHAIRMAN, PROMIS
United States Biopharmaceuticals 2018
ProMIS Neurosciences is a development-stage biotech company focused on neurodegenerative diseases, particularly Alzheimer’s disease and ALS.
M P Aggrawal
CHAIRMAN, SAJJAN INDIA LIMITED
Sajjan is an Indian contract manufacturer with expertise in large-scale production of active ingredients, electronic chemicals, specialty chemicals and intermediates with applications in agrochemicals, pharmaceuticals and dyes.
Bill Witham
CEO, AAMEG
AAMEG endeavors to provide Australian companies operating in Africa with a platform to network and discuss critical issues facing the industry today.
Adding Value to Turkey: Mineral Processing and Turkey’s Maturing Mining Industry
The recognition that Turkey’s miners must add more value to what they produce reflects the maturity of Turkey’s mining industry.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
